



News Updates: April 29, 2014

Patents/ Compulsory Licensing/ Intellectual Property

Publication: Business Standard

Edition: National

Date: April 29, 2014

Headline: [Govt for discussion paper on royalty payment ceiling](#)

Synopsis: Amid worries over a 50 per cent rise in royalty payments by Indian firms to their foreign partners or multinational parents in four years to 2012-13, the government is likely to bring a discussion paper for review of the present unbridled policy, after the Lok Sabha polls are over. "The discussion paper will come in the next couple of weeks," a senior official in the Department of Industrial Policy & Promotion (DIPP) said. The last phase of elections will be over on May 12.

Publication: The Telegraph

Edition: National

Date: April 29, 2014

Headline: [Bid to fight US trade threat](#)

Synopsis: India is exploring the possibility of dragging the US to the World Trade Organisation (WTO) if Washington imposes sanctions for alleged patent violations in medicines. The US Trade Representative on Wednesday will release a report on Special 301, which will include a list of priority foreign countries that deserve trade sanctions. A Priority Foreign Country tag is the worst classification of a country, under US trade laws, for denying protection to the intellectual property rights of American companies.

Publication: Business Standard

Edition: Chennai

Date: April 29, 2014

Headline: [Monetary relief to small units filing for patents online \(link unavailable, scan attached\)](#)

Synopsis: The amended patent rules give monetary relief to small entities filing for patents and trademarks online. However, awareness about intellectual property needs to be enhanced to boost filing of applications, according to Amitabh Kant, secretary, department of industrial policy and promotion (DIPP).

Clinical Trials

Publication: The New Indian Express

Edition: National

Date: April 29, 2014

Headline: [‘We Need Clinical Trials to Develop Affordable Drugs’](#)

Synopsis: The Association of Health Universities of India (AHUI) has called for lifting of restrictions on conducting clinical trials in order to develop affordable drugs. "If we want to grow in size, we need clinical trials," Dr Arun V Jamkar, Vice-Chancellor, Maharashtra University of Health Sciences (MUHS), Nashik and Chairman of the AHUI, said.

Drug pricing

Publication: Business Standard

Edition: National

Date: April 29, 2014

Headline: [Cipla faces fresh Rs 105-cr penalty for overcharging](#)

Synopsis: The National Pharmaceutical Pricing Authority (NPPA) recently issued fresh showcase notices to the company, asking why a Rs 105-crore fine shouldn't be imposed. The charge was that Cipla sold Cipro injection and Ciplox in the market allegedly at a price more than what was fixed, a senior official said. Another penalty decision of a little over Rs 1,700 crore is pending against the company the notices were issued this January), with similar allegations of overcharging on several medicines. Most of those are being appealed.

General Industry

Publication: The Economic Times

Edition: National

Date: April 29, 2014

Headline: [Pfizer still wants to pop AstraZeneca](#)

Synopsis: Pfizer publicly unveiled its interest in acquiring AstraZeneca of Britain on Monday, in what would be one of the biggest in an already swelling series of deal efforts among drug makers. In a statement, Pfizer said that it was willing to pay £58.7 billion, or \$98.7 billion. That would make it one of the largest ever acquisition efforts in the pharmaceutical industry, surpassing Pfizer's \$90 billion takeover of Warner-Lambert 14 years ago. Pfizer's prospective bid was valued at £46.61 a share, a roughly 30% premium to where AstraZeneca was trading at the beginning of the year.

Similar reports in-

Business Standard- [Pfizer says will pursue AstraZeneca](#)

The Times of India- [AstraZeneca rejects Pfizer's 2nd \\$100bn offer](#)

The Indian Express- [Pfizer prepares \\$98.9 billion bid for AstraZeneca](#)

Reuters- [AstraZeneca rejects Pfizer talks, says confident in strategy](#)

Publication: Business Standard

Edition: National

Date: April 29, 2014

Headline: [Natco Pharma US partner files ANDA for chemotherapy drug](#)

Synopsis: Breckenridge Pharmaceutical Inc, a marketing partner in the US for Hyderabad-based pharmaceutical and bulk chemicals manufacturer Natco Pharma Limited, has filed an abbreviated new drug application (ANDA) for bendamustine hydrochloride powder, intravenous infusion (25mg/vial and 100 mg/vial). Bendamustine hydrochloride powder is sold under the Treanda brand name by Teva Pharmaceutical Industries Limited's subsidiary Cephalon Inc. It is used as chemotherapy medicine.

Similar report in-

The Hindu Business Line- [Natco Pharma files for cancer drug generic](#)